Bruce Eaton - 05 Dec 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Reporting relationship: EVP, CBO AND CTO
Issuer ticker: EDIT
Reported as of: 05 Dec 2023
Net transaction value: -$1,122
SEC form: 4
Accepted by SEC: 07 Dec 2023, 16:30:36 UTC
Prior SEC filing: 16 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Bruce Eaton

Key filing fact

Bruce Eaton filed Form 4 for Editas Medicine, Inc. (EDIT) on 07 Dec 2023.

Key facts

This page summarizes Bruce Eaton's Form 4 filing for Editas Medicine, Inc. (EDIT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Dec 2023, 16:30.

Change

Previous filing in this sequence was filed on 16 Nov 2023.
Current net transaction value: -$1,122.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EDIT transaction

Common Stock

Sale

Transaction value: $1,122
Shares: -103
Change %: -0.14%
Price: $10.90
Shares after: 74,791
Date: 05 Dec 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $10.6149 to $10.9000. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.